Latest research on Dexmethylphenidate

Dexmethylphenidate is the dextrorotary form of methylphenidate. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Latest findings

The literature search revealed 18 relevant randomized, placebo-controlled trials with Methylphenidate in adults with ADHD, including one study with DexMethylphenidate (Wood et al 1976; Mattes et al 1984; Gualtieri et al 1985; Wender et al 1985; Spencer et al 1995, 2005, 2006; Kuperman et al 2001; Levin et al 2001, 2006, 2007; Schubiner et al 2002; Tenenbaum et al 2002; Bouffard et al 2003; Kooij et al 2004; Carpentier et al 2005; Biederman et al 2006; Reimherr et al 2007). [source, 2008]
Dexmethylphenidate, the chirally pure active isomer of methylphenidate, has been licensed as FocalinR (Novartis) in the US in May 2005, also as an extended-release formulation [49,52]. [source, 2007]